DOCSLIB.ORG

Highlights from the 2019 Advances in Inflammatory Bowel Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Highlights from the 2019 Advances in Inflammatory Bowel Diseases December 2019 Volume 15, Issue 12, Supplement 6 A SPECIAL MEETING REVIEW EDITION Highlights From the 2019 Advances in Inflammatory Bowel Diseases Conference A Review of Selected Presentations From the 2019 AIBD Conference • December 12-14, 2019 • Orlando, Florida Special Reporting on: • A Practical Approach to Anti-Interleukins in IBD 2020 • Update: ACG Guidelines for the Treatment of Crohn’s Disease • Management of Ulcerative Colitis in Adults: ACG Clinical Guidelines • The Road Ahead: Potential Benefits and Risks of Combining Biologics and Novel Agents • A Practical Approach to JAK inhibitors in IBD 2020 • A Practical Approach to Anti-Integrins in IBD 2020 • A Practical Approach to Anti-TNFs in IBD 2020 PLUS Meeting Abstract Summaries With Expert Commentary by: Gary R. Lichtenstein, MD Professor of Medicine Director, Center for Inflammatory Bowel Disease University of Pennsylvania Health System Hospital of the University of Pennsylvania Philadelphia, Pennsylvania ON THE WEB: gastroenterologyandhepatology.net Indexed through the National Library of Medicine (PubMed/Medline), PubMed Central (PMC), and EMBASE T:8.125" S:7.125" T:10.875" S:9.875" NOW APPROVED FOR A NEW INDICATION Learn more at StelaraHCP.com © Janssen Biotech, Inc. 2019 10/19 cp-108558v1 Date: November 18, 2019 8:16 AM Brand: STELARA® Colors: CMYK File Name: cp-108558v1_838723_v1 Size: 8 1/8 “ x 10 7/8” 85, 100, 9, 0 = Customer Code: cp-108558v1 Description: NOW APPROVED FOR A NEW INDICATION 49, 0, 21, 0 = Pub: AIBD Gastro & Hepatology and Gastro & Hepatology 2, 3, 96, 7 = We Are Alexander #: 838723 (December 2019 issues) HIGHLIGHTS FROM THE 2019 ADVANCES IN INFLAMMATORY BOWEL DISEASES CONFERENCE A Practical Approach to Anti-Interleukins in IBD 2020 r Bruce E. Sands discussed with ustekinumab (90 mg either every was associated with significantly higher the use of anti-interleukins.1 8 weeks or every 12 weeks) or placebo. corticosteroid-free remission rates at Ustekinumab is the only In both the UNITI-1 and week 44. This rate was 46.9% with the Danti-interleukin agent approved for UNITI-2 trials, a significantly higher every-8-week regimen, 42.6% with the the treatment of patients with IBD. proportion of patients who were treated every-12-week regimen, and 29.8% Through recognition of the shared with ustekinumab compared with pla- with placebo (P=.004 for the compari- p40 protein subunit, ustekinumab can cebo achieved the primary endpoint of son of every 8 weeks vs placebo; P=.035 disrupt proinflammatory cytokines clinical response (defined as a decrease for the comparison of every 12 weeks interleukin (IL) 12 and 23 signalling. of ≥100 points in the Crohn’s Disease vs placebo). In a long-term follow-up In patients with Crohn’s disease, the Activity Index [CDAI] from baseline of the UNITI studies, the rate of remis- pivotal induction trials establishing to week 6, or a CDAI score <150). In sion at 2 years among patients receiving the safety and efficacy of ustekinumab UNITI-1, the rates of response at week ustekinumab every 8 weeks was 47%, were UNITI-1 and UNITI-2.2 The 6 were 34.3% in the 130 mg arm and or 88% of the remission rate observed use of ustekinumab in the mainte- 33.7% in the 6 mg/kg arm, vs 21.5% at 1 year (53.1%; Figure 1).3 nance setting was established by the with placebo (P≤.003 for both com- Among patients with ulcerative IM-UNITI trial.2 In the UNITI-1 parisons with placebo). In UNITI-2, colitis, UNIFI was the pivotal induc- and UNITI-2 trials, patients were the rates of response at week 6 were tion and maintenance trial establishing randomly assigned to receive a single 51.7%, 55.5%, and 28.7%, respec- the safety and efficacy of ustekinumab intravenous dose of ustekinumab tively (P≤.001 for both comparisons in these settings.4 The trial randomly (either 130 mg or approximately 6 with placebo). assigned 961 patients with moderate to mg/kg) or placebo. The UNITI-1 trial The primary endpoint for the severe ulcerative colitis to ustekinumab enrolled 741 patients with a primary or IM-UNITI maintenance trial—remis- (130 mg or ~6 mg/kg) or placebo. secondary nonresponse to anti–tumor sion at week 44 (defined as a CDAI Patients with a response to induction necrosis factor (TNF) therapy, or score <150)—was also higher with therapy were randomly assigned again who developed unacceptable toxicity ustekinumab than placebo. This rate was to receive subcutaneous maintenance after treatment with these agents. The 53.1% with ustekinumab given every 8 injections of ustekinumab (90 mg UNITI-2 trial enrolled 628 patients weeks and 48.8% with ustekinumab every 8 weeks or every 12 weeks) or with an inadequate response to con- given every 12 weeks, vs 35.9% with placebo. ventional therapy or who were intoler- placebo (P=.005 for the comparison The primary endpoint of clinical ant to it. Patients with a response in of every 8 weeks vs placebo; P=.04 for remission was defined as a total score either UNITI-1 or UNITI-2 (n=397) the comparison of every 12 weeks vs of 2 or less on the Mayo scale and no were randomly assigned to treatment placebo). Treatment with ustekinumab subscore exceeding 1 on any of the 70 53% 47% of patients in remission of patients in remission 52 weeks after induction 60 100 weeks after induction 50 40 30 20 Placebo (n=131) Ustekinumab 90 mg every 8 weeks (n=128) Proportion of Patients (%) Proportion of Patients 10 Entry into long-term extension 0 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 Entry into maintenance from Weeks After Induction 8-week induction Figure 1. Remission through 2 years among patients with Crohn’s disease responding to induction treatment with ustekinumab in the IM-UNITI long-term extension study. Adapted from Sands BE et al. ACG abstract 49. Presented at: American College of Gastroenterology Annual Scientific Meeting; October 5-10, 2018; Philadelphia, PA3 and Sands BE. A practical approach to anti-interleukins in IBD 2020. Paper presented at: Advances in Inflammatory Bowel Diseases Conference; December 12-14, 2019; Orlando, Florida.1 Gastroenterology & Hepatology Volume 15, Issue 12, Supplement 6 December 2019 3 SPECIAL MEETING REVIEW EDITION 4 Mayo scale components. The rate 100 P<.001 of clinical remission at week 8 was P<.001 15.6% with ustekinumab at 130 mg, 80 71.0 15.5% with ustekinumab at 6 mg/kg, 68.0 and 5.3% with placebo (P<.001 for 60 both comparisons to placebo). Among 44.6 responding patients, the rate of clini- 40 cal remission at week 44 was 43.8% with ustekinumab given every 8 weeks, 20 38.4% with ustekinumab given every 12 weeks, and 24.0% with placebo Proportion of Patients (%) Proportion of Patients 78/175 117/172 125/176 0 (P=.002 and P<.001, respectively). Other outcomes through week 44 are shown in Figures 2 and 3.5 Long-term Placebo SCa Ustekinumab Ustekinumab 90 mg SC q12w 90 mg SC q8w symptomatic remission was observed in the group of patients who continued to receive ustekinumab in a long-term Figure 2. Clinical response through week 44 among patients with ulcerative colitis treated with extension trial.6 a ustekinumab in the UNIFI trial. Patients with a clinical response to intravenous ustekinumab In summary, ustekinumab was and were randomized to subcutaneous placebo upon entry into the maintenance study. q8w, effective in Crohn’s disease and ulcer- every 8 weeks; q12w, every 12 weeks; SC, subcutaneous. Adapted from Sandborn WJ et al. ative colitis, where it may be useful ECCO abstract OP37. J Crohns Colitis. 2019;13(suppl 1)5 and Sands BE. A practical approach in both the first-line setting and after to anti-interleukins in IBD 2020. Paper presented at: Advances in Inflammatory Bowel Diseases Conference; December 12-14, 2019; Orlando, Florida.1 anti-TNF agent failure. Ustekinumab confers a very good corticosteroid spar- ing and maintenance effect. The onset of efficacy associated with ustekinumab Placebo (n=175) was observed as early as 2 weeks, but Ustekinumab, 90 mg every 12 weeks (n=172) efficacy can increase over 16 weeks and beyond. The safety of ustekinumab has Ustekinumab, 90 mg every 8 weeks (n=176) been well established, with minimal immunogenicity and a minimal need P=.07 for laboratory monitoring. 100 References 90 P=.01 1. Sands BE. A practical approach to anti-interleukins in IBD 2020. Paper presented at: 2019 Advances in 80 65 Inflammatory Bowel Diseases Conference; December 70 (n=40) 58 12-14, 2019; Orlando, Florida. (n=38) 2. Feagan BG, Sandborn WJ, Gasink C, et al; UNITI– 60 IM-UNITI Study Group. Ustekinumab as induction 38 and maintenance therapy for Crohn’s disease. N Engl J 50 Med. 2016;375(20):1946-1960. (n=45) 3. Sands BE, Kramer BC, Gasink C, et al. Long-term 40 efficacy and safety of ustekinumab with and without 30 concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 20 two years. Presented at: American College of Gastro- Patients at Week 44 (%) Week at Patients enterology Annual Scientific Meeting; October 5-10, 10 2018; Philadelphia, PA. Abstract 49. 4. Sands BE, Sandborn WJ, Panaccione R, et al; UNIFI 0 Study Group. Ustekinumab as induction and main- Remission Through Week 44 tenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201-1214. Among Those in Remission 5. Sandborn WJ, Sands BE, Panaccione R, et al.
Load more

Recommended publications
  • Recent Advances in Inflammatory Bowel Disease: Mucosal Immune
    Recent advances in basic science Recent advances in inflammatory bowel disease: Gut: first published as 10.1136/gutjnl-2012-303955 on 8 October 2013. Downloaded from mucosal immune cells in intestinal inflammation M Zaeem Cader,1,2 Arthur Kaser1 1Department of Medicine, ABSTRACT Recent years have seen a rapid and exciting Division of Gastroenterology & The intestine and its immune system have evolved to expansion in our understanding of the mucosal Hepatology, University of Cambridge, Addenbrooke’s meet the extraordinary task of maintaining tolerance to immune system with novel insights into environ- Hospital, Cambridge, UK the largest, most complex and diverse microbial mental influences of diet and the microbiota; the 2Wellcome Trust PhD commensal habitat, while meticulously attacking and convergence and integration of fundamental cellu- Programme for Clinicians, containing even minute numbers of occasionally lar processes such as autophagy, microbial sensing Cambridge Institute for incoming pathogens. While our understanding is still far and endoplasmic reticulum (ER) stress; as well as Medical Research, School of Clinical Medicine, University of from complete, recent studies have provided exciting the discovery of new cell types, for example innate Cambridge, Cambridge, UK novel insights into the complex interplay of the many lymphoid cells (ILCs). distinct intestinal immune cell types as well as the The gut is unlike the systemic immune system in Correspondence to discovery of entirely new cell subsets. These studies have several respects and much of the extensive reper- Dr Arthur Kaser, Department of Medicine, Division of also revealed how proper development and function of toire of immune cells and their characteristics are Gastroenterology and the intestinal immune system is dependent on its specific indeed unique to the intestine.
    [Show full text]
  • HY 2021 Results
    Roche HY 2021 results Basel, 22 July 2021 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.
    [Show full text]
  • Immunfarmakológia Immunfarmakológia
    Gergely: Immunfarmakológia Immunfarmakológia Prof Gergely Péter Az immunpatológiai betegségek döntő többsége gyulladásos, és ennek következtében általában szövetpusztulással járó betegség, melyben – jelenleg – a terápia alapvetően a gyulladás csökkentésére és/vagy megszűntetésére irányul. Vannak kizárólag gyulladásgátló gyógyszereink és vannak olyanok, amelyek az immunreakció(k) bénításával (=immunszuppresszió révén) vagy emellett vezetnek a gyulladás mérsékléséhez. Mind szerkezetileg, mind hatástanilag igen sokféle csoportba oszthatók, az alábbi felosztás elsősorban didaktikus célokat szolgál. 1. Nem-szteroid gyulladásgátlók (‘nonsteroidal antiinflammatory drugs’ NSAID) 2. Kortikoszteroidok 3. Allergia-elleni szerek (antiallergikumok) 4. Sejtoszlás-gátlók (citosztatikumok) 5. Nem citosztatikus hatású immunszuppresszív szerek 6. Egyéb gyulladásgátlók és immunmoduláns szerek 7. Biológiai terápia 1. Nem-szteroid gyulladásgátlók (NSAID) Ezeket a vegyületeket, melyek őse a szalicilsav (jelenleg, mint acetilszalicilsav ‘aszpirin’ használatos), igen kiterjedten alkalmazzák a reumatológiában, az onkológiában és az orvostudomány szinte minden ágában, ahol fájdalom- és lázcsillapításra van szükség. Egyes felmérések szerint a betegek egy ötöde szed valamilyen NSAID készítményt. Szerkezetük alapján a készítményeket több csoportba sorolhatjuk: szalicilátok (pl. acetilszalicilsav) pyrazolidinek (pl. fenilbutazon) ecetsav származékok (pl. indometacin) fenoxiecetsav származékok (pl. diclofenac, aceclofenac)) oxicamok (pl. piroxicam, meloxicam) propionsav
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • Novel Therapies for Eosinophilic Disorders
    Novel Therapies for Eosinophilic Disorders Bruce S. Bochner, MD KEYWORDS Eosinophil Therapies Antibodies Targets Pharmacology Biomarkers KEY POINTS A sizable unmet need exists for new, safe, selective, and effective treatments for eosinophil-associated diseases, such as hypereosinophilic syndrome, eosinophilic gastrointestinal disorders, nasal polyposis, and severe asthma. An improved panel of biomarkers to help guide diagnosis, treatment, and assessment of disease activity is also needed. An impressive array of novel therapeutic agents, including small molecules and biologics, that directly or indirectly target eosinophils and eosinophilic inflammation are undergoing controlled clinical trials, with many already showing promising results. A large list of additional eosinophil-related potential therapeutic targets remains to be pursued, including cell surface structures, soluble proteins that influence eosinophil biology, and eosinophil-derived mediators that have the potential to contribute adversely to disease pathophysiology. INTRODUCTION Eosinophilic disorders, also referred to as eosinophil-associated diseases, consist of a range of infrequent conditions affecting virtually any body compartment and organ.1 The most commonly affected areas include the bone marrow, blood, mucosal sur- faces, and skin, often with immense disease- and treatment-related morbidity, Disclosure Statement: Dr Bochner’s research efforts are supported by grants AI072265, AI097073 and HL107151 from the National Institutes of Health. He has current or recent consul- ting or scientific advisory board arrangements with, or has received honoraria from, Sanofi-A- ventis, Pfizer, Svelte Medical Systems, Biogen Idec, TEVA, and Allakos, Inc. and owns stock in Allakos, Inc. and Glycomimetics, Inc. He receives publication-related royalty payments from Elsevier and UpToDate and is a coinventor on existing and pending Siglec-8-related patents and, thus, may be entitled to a share of future royalties received by Johns Hopkins University on the potential sales of such products.
    [Show full text]
  • Roche Investor Presentation Oppenheimer 23Rd Annual
    Roche: Oppenheimer 23rd Annual Healthcare Conference Thomas Kudsk Larsen, Head of Investor Relations North America, New York, 12 December 2012 Forward-looking statements This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1. pricing and product initiatives of competitors; 2. legislative and regulatory developments and economic conditions; 3. delay or inability in obtaining regulatory approvals or bringing products to market; 4. fluctuations in currency exchange rates and general financial market conditions; 5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6. increased government pricing pressures; 7. interruptions in production; 8. loss of or inability to obtain adequate protection for intellectual property rights; 9. Litigation; 10. loss of key executives or other employees; and 11. adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website2 www.roche.com.
    [Show full text]
  • Minutes PDCO 25-28 February 2020
    26 February 2020 EMA/PDCO/104692/2020 Inspections, Human Medicines Pharmacovigilance and Committees Division Paediatric Committee (PDCO) Minutes for the meeting on 25-28 February 2020 Chair: Koenraad Norga – Vice-Chair: Sabine Scherer Disclaimers Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes. Further information with relevant explanatory notes can be found at the end of this document. Note on access to documents Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020.
    [Show full text]
  • Microbiota and Drug Response in Inflammatory Bowel Disease
    pathogens Review Microbiota and Drug Response in Inflammatory Bowel Disease Martina Franzin 1,† , Katja Stefanˇciˇc 2,† , Marianna Lucafò 3, Giuliana Decorti 1,3,* and Gabriele Stocco 2 1 Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy; [email protected] 2 Department of Life Sciences, University of Trieste, 34127 Trieste, Italy; [email protected] (K.S.); [email protected] (G.S.) 3 Institute for Maternal and Child Health—IRCCS “Burlo Garofolo”, 34137 Trieste, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-3785362 † The authors contributed equally to the manuscript. Abstract: A mutualistic relationship between the composition, function and activity of the gut microbiota (GM) and the host exists, and the alteration of GM, sometimes referred as dysbiosis, is involved in various immune-mediated diseases, including inflammatory bowel disease (IBD). Accumulating evidence suggests that the GM is able to influence the efficacy of the pharmacological therapy of IBD and to predict whether individuals will respond to treatment. Additionally, the drugs used to treat IBD can modualate the microbial composition. The review aims to investigate the impact of the GM on the pharmacological therapy of IBD and vice versa. The GM resulted in an increase or decrease in therapeutic responses to treatment, but also to biotransform drugs to toxic metabolites. In particular, the baseline GM composition can help to predict if patients will respond to the IBD treatment with biologic drugs. On the other hand, drugs can affect the GM by incrementing or reducing its diversity and richness. Therefore, the relationship between the GM and drugs used in Citation: Franzin, M.; Stefanˇciˇc,K.; the treatment of IBD can be either beneficial or disadvantageous.
    [Show full text]
  • Biological Treatments in Inflammatory Bowel Disease: a Complex Mix Of
    Review Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions Lorena Ortega Moreno 1,2,3 , Samuel Fernández-Tomé 1,3 and Raquel Abalo 4,5,6,7,* 1 Instituto de Investigación Sanitaria Hospital Universitario de La Princesa, 28006 Madrid, Spain; [email protected] (L.O.M.); [email protected] (S.F.-T.) 2 Department of Medicine, Faculty of Medicine, Universidad Autónoma de Madrid, 28049 Madrid, Spain 3 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain 4 Department of Basic Health Sciences, Faculty of Health Sciences, University Rey Juan Carlos (URJC), 28922 Alcorcón, Spain 5 High Performance Research Group in Physiopathology and Pharmacology of the Digestive System (NeuGut-URJC), URJC, 28922 Alcorcón, Spain 6 Associated I+D+i Unit to the Institute of Medicinal Chemistry (IQM), Scientific Research Superior Council (CSIC), 28006 Madrid, Spain 7 Working Group of Basic Sciences in Pain and Analgesia of the Spanish Pain Society (Grupo de Trabajo de Ciencias Básicas en Dolor y Analgesia de la Sociedad Española del Dolor), 28046 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-91-488-8854 Abstract: Inflammatory bowel disease (IBD) is a chronic disease that requires lifelong medication and whose incidence is increasing over the world. There is currently no cure for IBD, and the current ther- apeutic objective is to control the inflammatory process. Approximately one third of treated patients do not respond to treatment and refractoriness to treatment is common. Therefore, pharmacological Citation: Moreno, L.O.; treatments, such as monoclonal antibodies, are urgently needed, and new treatment guidelines are Fernández-Tomé, S.; Abalo, R.
    [Show full text]
  • INN Working Document 05.179 Update 2011
    INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • The Current State of the Art for Biological Therapies and New Small Molecules in Inflammatory Bowel Disease
    www.nature.com/mi REVIEW ARTICLE The current state of the art for biological therapies and new small molecules in inflammatory bowel disease Sudarshan Paramsothy1, Adam K. Rosenstein1,2, Saurabh Mehandru1,2 and Jean-Frederic Colombel1 The emergence of biologic therapies is arguably the greatest therapeutic advance in the care of inflammatory bowel disease (IBD) to date, allowing directed treatments targeted at highly specific molecules shown to play critical roles in disease pathogenesis, with advantages in potency and selectivity. Furthermore, a large number of new biologic and small-molecule therapies in IBD targeting a variety of pathways are at various stages of development that should soon lead to a dramatic expansion in our therapeutic armamentarium. Additionally, since the initial introduction of biologics, there have been substantial advances in our understanding as to how biologics work, the practical realities of their administration, and how to enhance their efficacy and safety in the clinical setting. In this review, we will summarize the current state of the art for biological therapies in IBD, both in terms of agents available and their optimal use, as well as preview future advances in biologics and highly targeted small molecules in the IBD field. Mucosal Immunology (2018) 11:1558–1570; https://doi.org/10.1038/s41385-018-0050-3 INTRODUCTION concerns regarding the safety of these agents have decreased Inflammatory bowel disease (IBD) incorporates a spectrum of with accumulating data. Although there is a slightly increased risk chronic, often progressive and disabling, inflammatory disorders of serious infections, this is lower than initially predicted and less of the gastrointestinal tract including Crohn’s disease (CD) and than the risk associated with steroid use.12 Concerns regarding ulcerative colitis (UC).
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]